Simcere Pharmaceutical Group and Epitomics, Inc. Form mAb Development Partnership

ChinaBio Today -- Simcere Pharma and San Francisco-based Epitomics, Inc. will collaborate to develop anti-cancer drugs using RabMAb®, Epitomics’ humanized rabbit monoclonal antibodies. Until now, Epitomics has concentrated its efforts on applying RabMAb® to develop diagnostic tools. The Simcere collaboration will be the first attempt to develop humanized antibody therapeutics from the rabbit antibodies.

MORE ON THIS TOPIC